<i>Cannabis sativa</i> L. as a Natural Drug Meeting the Criteria of a Multitarget Approach to Treatment
<i>Cannabis sativa</i> L. turned out to be a valuable source of chemical compounds of various structures, showing pharmacological activity. The most important groups of compounds include phytocannabinoids and terpenes. The pharmacological activity of <i>Cannabis</i> (in epile...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2021-01-01
|
| Series: | International Journal of Molecular Sciences |
| Subjects: | |
| Online Access: | https://www.mdpi.com/1422-0067/22/2/778 |
| _version_ | 1797411717170331648 |
|---|---|
| author | Anna Stasiłowicz Anna Tomala Irma Podolak Judyta Cielecka-Piontek |
| author_facet | Anna Stasiłowicz Anna Tomala Irma Podolak Judyta Cielecka-Piontek |
| author_sort | Anna Stasiłowicz |
| collection | DOAJ |
| description | <i>Cannabis sativa</i> L. turned out to be a valuable source of chemical compounds of various structures, showing pharmacological activity. The most important groups of compounds include phytocannabinoids and terpenes. The pharmacological activity of <i>Cannabis</i> (in epilepsy, sclerosis multiplex (SM), vomiting and nausea, pain, appetite loss, inflammatory bowel diseases (IBDs), Parkinson’s disease, Tourette’s syndrome, schizophrenia, glaucoma, and coronavirus disease 2019 (COVID-19)), which has been proven so far, results from the affinity of these compounds predominantly for the receptors of the endocannabinoid system (the cannabinoid receptor type 1 (CB<sub>1</sub>), type two (CB<sub>2</sub>), and the G protein-coupled receptor 55 (GPR<sub>55</sub>)) but, also, for peroxisome proliferator-activated receptor (PPAR), glycine receptors, serotonin receptors (5-HT), transient receptor potential channels (TRP), and GPR, opioid receptors. The synergism of action of phytochemicals present in <i>Cannabis</i> sp. raw material is also expressed in their increased bioavailability and penetration through the blood–brain barrier. This review provides an overview of phytochemistry and pharmacology of compounds present in <i>Cannabis</i> extracts in the context of the current knowledge about their synergistic actions and the implications of clinical use in the treatment of selected diseases. |
| first_indexed | 2024-03-09T04:49:08Z |
| format | Article |
| id | doaj.art-b5d3230628f84d80bb5ac134cee37a28 |
| institution | Directory Open Access Journal |
| issn | 1661-6596 1422-0067 |
| language | English |
| last_indexed | 2024-03-09T04:49:08Z |
| publishDate | 2021-01-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | International Journal of Molecular Sciences |
| spelling | doaj.art-b5d3230628f84d80bb5ac134cee37a282023-12-03T13:12:07ZengMDPI AGInternational Journal of Molecular Sciences1661-65961422-00672021-01-0122277810.3390/ijms22020778<i>Cannabis sativa</i> L. as a Natural Drug Meeting the Criteria of a Multitarget Approach to TreatmentAnna Stasiłowicz0Anna Tomala1Irma Podolak2Judyta Cielecka-Piontek3Department of Pharmacognosy, Poznan University of Medical Sciences, Swiecickiego 4, 61-781 Poznan, PolandDepartment of Pharmacognosy, Medical College, Jagiellonian University, Medyczna 9, 30-688 Cracow, PolandDepartment of Pharmacognosy, Medical College, Jagiellonian University, Medyczna 9, 30-688 Cracow, PolandDepartment of Pharmacognosy, Poznan University of Medical Sciences, Swiecickiego 4, 61-781 Poznan, Poland<i>Cannabis sativa</i> L. turned out to be a valuable source of chemical compounds of various structures, showing pharmacological activity. The most important groups of compounds include phytocannabinoids and terpenes. The pharmacological activity of <i>Cannabis</i> (in epilepsy, sclerosis multiplex (SM), vomiting and nausea, pain, appetite loss, inflammatory bowel diseases (IBDs), Parkinson’s disease, Tourette’s syndrome, schizophrenia, glaucoma, and coronavirus disease 2019 (COVID-19)), which has been proven so far, results from the affinity of these compounds predominantly for the receptors of the endocannabinoid system (the cannabinoid receptor type 1 (CB<sub>1</sub>), type two (CB<sub>2</sub>), and the G protein-coupled receptor 55 (GPR<sub>55</sub>)) but, also, for peroxisome proliferator-activated receptor (PPAR), glycine receptors, serotonin receptors (5-HT), transient receptor potential channels (TRP), and GPR, opioid receptors. The synergism of action of phytochemicals present in <i>Cannabis</i> sp. raw material is also expressed in their increased bioavailability and penetration through the blood–brain barrier. This review provides an overview of phytochemistry and pharmacology of compounds present in <i>Cannabis</i> extracts in the context of the current knowledge about their synergistic actions and the implications of clinical use in the treatment of selected diseases.https://www.mdpi.com/1422-0067/22/2/778<i>Cannabis</i>phytocannabinoids (THC and CBD)terpenesmultitargetreceptors |
| spellingShingle | Anna Stasiłowicz Anna Tomala Irma Podolak Judyta Cielecka-Piontek <i>Cannabis sativa</i> L. as a Natural Drug Meeting the Criteria of a Multitarget Approach to Treatment International Journal of Molecular Sciences <i>Cannabis</i> phytocannabinoids (THC and CBD) terpenes multitarget receptors |
| title | <i>Cannabis sativa</i> L. as a Natural Drug Meeting the Criteria of a Multitarget Approach to Treatment |
| title_full | <i>Cannabis sativa</i> L. as a Natural Drug Meeting the Criteria of a Multitarget Approach to Treatment |
| title_fullStr | <i>Cannabis sativa</i> L. as a Natural Drug Meeting the Criteria of a Multitarget Approach to Treatment |
| title_full_unstemmed | <i>Cannabis sativa</i> L. as a Natural Drug Meeting the Criteria of a Multitarget Approach to Treatment |
| title_short | <i>Cannabis sativa</i> L. as a Natural Drug Meeting the Criteria of a Multitarget Approach to Treatment |
| title_sort | i cannabis sativa i l as a natural drug meeting the criteria of a multitarget approach to treatment |
| topic | <i>Cannabis</i> phytocannabinoids (THC and CBD) terpenes multitarget receptors |
| url | https://www.mdpi.com/1422-0067/22/2/778 |
| work_keys_str_mv | AT annastasiłowicz icannabissativailasanaturaldrugmeetingthecriteriaofamultitargetapproachtotreatment AT annatomala icannabissativailasanaturaldrugmeetingthecriteriaofamultitargetapproachtotreatment AT irmapodolak icannabissativailasanaturaldrugmeetingthecriteriaofamultitargetapproachtotreatment AT judytacieleckapiontek icannabissativailasanaturaldrugmeetingthecriteriaofamultitargetapproachtotreatment |